Key Takeaways:Solabia strengthens its positioning in cosmetics and diagnostics with another transaction.This deal will also secure a critical raw-material supply for Solabia to support its diagnostic activities.Seqens is divesting its Botanical Actives and In Vitro Diagnostics activities in the transaction.Backed by private equity firm Astorg, Solabia continues to strengthen its leadership in cosmetic ingredients and diagnostics solutions with the acquisition.WHO: Seqens is an integrated player across the entire value chain—from raw materials to active ingredients and from R&D to industrialization. Seqens offers a broad portfolio of active pharmaceutical ingredients, pharmaceutical intermediates, and specialty ingredients, develops and industrializes the most complex molecules, and leverages its ability to innovate, develop, and implement the best available technologies. Seqens has 15 production sites, five R&D centers, and 2,700 employees across three continents.The business operates a facility in Limoges, France, recognized for its advanced botanical extraction and high-end manufacturing capabilities. Its ingredients and diagnostic solutions are commercialized worldwide and used by leading brands across both sectors.Founded in 1972, Solabia is a vertically integrated manufacturer of natural active ingredients for the cosmetics, nutraceutical, pharmaceutical, biotechnology, and microbiology industries. Solabia is also a producer of culture media, supplements, and detection kits for food testing, pharmaceutical industry, and microbiology laboratories.